Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Cicuta Virosa
Brand Name
Cicuta Virosa
Generic Name
Cicuta Virosa
Active Ingredient
Cicuta Virosa RootCategory
Standardized Insect Venom Allergenic Extract [EPC]
Variants
8
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 200 [hp_C]/1 | PELLET | ORAL | 37662-0295 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-0291 |
| 10 [hp_M]/1 | PELLET | ORAL | 37662-0298 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Cicuta Virosa, you must consult a qualified healthcare professional.
| 12 [hp_C]/1 | PELLET | ORAL | 37662-0292 |
| 30 [hp_C]/1 | PELLET | ORAL | 37662-0293 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-0294 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-0296 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-0297 |
Detailed information about Cicuta Virosa
Cicuta Virosa Root is a potent botanical extract classified as a Standardized Insect Venom Allergenic Extract and Anticholinergic. It is primarily utilized in specialized clinical diagnostics and immunological research under strict medical supervision.
Dosage for Cicuta Virosa Root must be highly individualized and is strictly determined by the clinical indication and the patient's sensitivity profile.
Cicuta Virosa Root is generally not recommended for use in pediatric populations unless the benefits of diagnostic allergy testing significantly outweigh the risks of systemic toxicity. If used, dosing must be adjusted based on the child's weight (mg/kg) and must be performed in a pediatric intensive care or specialized allergy unit. There is no established safety profile for children under the age of 12 for most standardized extracts of this nature.
Patients with impaired kidney function may experience decreased clearance of the metabolites of Cicuta Virosa. While specific GFR (Glomerular Filtration Rate) adjustments are not standardized, clinicians are advised to use the lowest effective diagnostic dose and monitor for signs of prolonged anticholinergic activity.
Because the liver is the primary site of metabolism for cicutoxin and related alkaloids, patients with hepatic cirrhosis or acute liver failure are at a significantly increased risk of toxicity. Dose reductions of 50% or more may be necessary, and in severe cases, the use of this agent may be contraindicated.
Geriatric patients are more sensitive to the anticholinergic effects of Cicuta Virosa Root. There is an increased risk of confusion, urinary retention, and acute glaucoma in this population. Dosing should start at the absolute minimum of the therapeutic range.
This medication is almost exclusively administered by a healthcare professional.
As this medication is usually administered in a clinical setting for specific diagnostic or therapeutic sessions, a missed dose should be rescheduled as soon as possible. Do not attempt to 'double up' on doses if a clinical appointment is missed.
An overdose of Cicuta Virosa Root is a medical emergency. Signs of overdose include:
Emergency Measures: If an overdose is suspected, immediate gastric lavage (if ingested) and the administration of activated charcoal are required. Seizures are typically managed with high-dose benzodiazepines (like diazepam or lorazepam) or barbiturates. There is no specific antidote for cicutoxin; treatment is primarily supportive and symptomatic.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to source this botanical material independently without medical guidance.
Patients undergoing diagnostic testing or treatment with Cicuta Virosa Root standardized extracts frequently report localized reactions. These include:
Cicuta Virosa Root is one of the most pharmacologically active and potentially dangerous botanical substances known to medical science. Its use as a Standardized Insect Venom Allergenic Extract and Anticholinergic requires extreme caution. Patients must be aware that even small deviations in concentration or administration technique can result in systemic toxicity. It is imperative that this medication is only used in a controlled clinical environment.
No official FDA black box warning exists for the homeopathic or highly diluted versions; however, for the standardized clinical extract, the following warning is standard in toxicological literature:
Certain medications must never be combined with Cicuta Virosa Root due to the risk of fatal interactions:
Cicuta Virosa Root must NEVER be used in the following circumstances:
Cicuta Virosa Root is generally classified as Pregnancy Category C (or Category D in high concentrations). There are no adequate, well-controlled studies in pregnant women. Animal studies have shown that cicutoxin can be teratogenic (causing birth defects) and may induce uterine contractions due to its complex effect on smooth muscle and adrenergic receptors. Its use during pregnancy should be restricted to situations where the mother's life is at risk from a severe allergy and no alternative diagnostic tool is available. Exposure during the first trimester is particularly discouraged due to the risk of neurological developmental interference.
It is unknown whether the active alkaloids of Cicuta Virosa Root are excreted in human milk. However, due to their low molecular weight and lipophilic nature, passage into breast milk is highly likely. Because of the extreme sensitivity of the infant nervous system to convulsants, breastfeeding should be discontinued for at least 48 to 72 hours following the administration of this agent. Always consult with a lactation specialist and your physician.
Cicuta Virosa Root acts primarily as a non-competitive antagonist of Gamma-Aminobutyric Acid (GABA) receptors in the central nervous system. Specifically, the active compound cicutoxin binds to the GABA-A receptor-chloride channel complex, preventing the inhibitory neurotransmitter GABA from binding. This leads to unchecked neuronal excitation, which manifests clinically as seizures.
Additionally, its classification as a Cholinergic Muscarinic Antagonist indicates that it binds to M1, M2, and M3 receptors. This blockade prevents acetylcholine from inducing parasympathetic responses, leading to the 'drying' effects and heart rate increases. Its Adrenergic Agonist properties involve the stimulation of alpha-1, beta-1, and beta-2 receptors, contributing to its complex cardiovascular profile.
The onset of action for the standardized extract is rapid, typically occurring within 15 to 30 minutes of subcutaneous administration. The duration of the anticholinergic effect can last from 4 to 12 hours, while the pro-convulsant effects on the CNS are most acute in the first 2 hours. There is a very narrow therapeutic index; the difference between a diagnostic dose and a toxic dose is minimal.
Common questions about Cicuta Virosa
Cicuta Virosa Root is primarily used in specialized medical settings as a standardized allergenic extract for diagnostic testing. It helps healthcare providers identify patients who have life-threatening allergies to certain insect venoms. Additionally, it possesses anticholinergic properties, meaning it can be used to block certain nerve impulses to treat specific conditions involving the parasympathetic nervous system. Because of its extreme potency and natural toxicity, it is never used for self-medication. It is always administered by a trained professional in a clinical environment.
The most common side effects are localized to the area where the extract is injected, including redness, itching, and swelling. Many patients also experience systemic anticholinergic effects such as dry mouth, blurred vision, and a slight increase in heart rate. Some individuals may feel dizzy or develop a mild headache shortly after the procedure. These symptoms are usually temporary and subside as the drug is metabolized. However, any side effect should be reported to the attending clinician immediately.
No, you should strictly avoid alcohol before and after receiving Cicuta Virosa Root. Alcohol can significantly increase the risk of central nervous system side effects and lower the threshold for seizures, which is a major risk with this specific substance. Combining alcohol with an anticholinergic agent can also lead to severe dehydration and heatstroke because the body's ability to sweat is suppressed. It is best to wait at least 24 to 48 hours after the procedure before consuming any alcoholic beverages. Always follow the specific recovery instructions provided by your doctor.
Cicuta Virosa Root is generally not considered safe during pregnancy and is classified as Category C or D. There is evidence from animal studies that the active toxins in the root can cause developmental harm to the fetus and may trigger uterine contractions. It should only be used in pregnant women if the diagnostic need is absolute and no safer alternatives exist. If you are pregnant or planning to become pregnant, you must inform your doctor before undergoing any testing with this extract. The potential for maternal seizures also poses a grave risk to the unborn child.
When used for allergy testing, the effects of Cicuta Virosa Root are very rapid, often appearing within 15 to 30 minutes of administration. The clinician will look for a 'wheal and flare' reaction on the skin as a sign of a positive diagnostic result. Systemic effects, such as changes in heart rate or mouth dryness, can also occur within this same timeframe. Because the onset is so fast, patients are required to stay in the clinic for observation. The total duration of the drug's effect on the body typically lasts between 4 and 12 hours.
Since Cicuta Virosa Root is typically administered as a one-time diagnostic dose or in specific clinical sessions, 'stopping' it in the traditional sense of a daily pill does not apply. However, if you are undergoing a series of immunotherapy treatments, you should not miss a session without consulting your doctor. Stopping a desensitization protocol abruptly can reset your allergy sensitivity levels. There is no physical withdrawal syndrome associated with a single dose, but you may experience a return of original symptoms if the drug was being used for its anticholinergic effects.
If you miss an appointment for a Cicuta Virosa Root administration, contact your healthcare provider's office immediately to reschedule. Because the concentration and timing of these doses are critical for both safety and diagnostic accuracy, you should not attempt to adjust the schedule yourself. Missing a diagnostic test simply means the information needed for your treatment plan will be delayed. If the drug is being used for immunotherapy, your doctor will determine the safest way to resume the schedule, which may involve repeating a previous lower dose.
There is no clinical evidence to suggest that Cicuta Virosa Root causes weight gain. Because it is used in short-term diagnostic or therapeutic intervals rather than as a chronic daily medication, it does not have the opportunity to affect metabolic rates or appetite in a way that leads to weight changes. If you notice sudden weight gain or swelling (edema) after treatment, it is more likely related to a localized allergic reaction or an underlying condition. Always discuss any unexpected physical changes with your medical team.
Cicuta Virosa Root has many significant drug interactions, particularly with other anticholinergics, antidepressants, and seizure medications. It is vital that you provide your doctor with a complete list of everything you are taking, including herbal supplements like St. John's Wort. Some medications can make the side effects of Cicuta Virosa much more dangerous, especially those that affect the heart or the brain's seizure threshold. Your doctor may ask you to temporarily stop certain medications before your appointment to ensure the test is safe and accurate.
Cicuta Virosa Root is a specialized botanical extract and is not typically marketed under a 'brand vs. generic' system like common antibiotics or blood pressure pills. It is available as a standardized pharmaceutical extract from various specialized laboratories that produce allergenic products. While different companies may manufacture the extract, they are all required to meet strict FDA standards for potency and purity. You cannot purchase this medication at a standard retail pharmacy; it is sourced directly by hospitals and specialty clinics.
Other drugs with the same active ingredient (Cicuta Virosa Root)
These effects may indicate a mild systemic absorption of the extract:
Rare but serious reactions that require close monitoring include:
> Warning: Stop the procedure and call for emergency medical help immediately if you experience any of the following symptoms. These may indicate systemic poisoning or anaphylaxis.
Because Cicuta Virosa Root is typically used for short-term diagnostic or specific therapeutic intervals, long-term data in humans are sparse. However, prolonged exposure to its anticholinergic components can lead to chronic dry eye, persistent constipation, and cognitive decline in vulnerable populations. In cases of survived acute poisoning, some patients have reported long-term retrograde amnesia (loss of memory for events leading up to the poisoning) and persistent neurological hypersensitivity.
While the FDA has not issued a specific 'Black Box' warning for the standardized extract in the same way as for high-volume pharmaceuticals, the clinical literature emphasizes a Major Safety Warning:
Report any unusual symptoms or persistent side effects to your healthcare provider immediately.
Patients receiving Cicuta Virosa Root extracts require the following monitoring:
Cicuta Virosa Root can cause significant dizziness, blurred vision, and cognitive clouding. Patients should not drive, operate heavy machinery, or engage in hazardous activities for at least 24 hours following the administration of a clinical dose, or until they are certain the effects have fully dissipated.
Alcohol should be strictly avoided. Ethanol can potentiate the CNS effects of the drug and may lower the seizure threshold further, increasing the risk of a catastrophic neurological event.
In the context of diagnostic testing, discontinuation is immediate upon completion of the test. For patients receiving it as part of a therapeutic protocol (e.g., immunotherapy), tapering is generally not required due to the low cumulative doses, but patients should be monitored for 'rebound' cholinergic symptoms such as increased salivation or gastric distress.
> Important: Discuss all your medical conditions, especially neurological and cardiac history, with your healthcare provider before starting Cicuta Virosa Root.
Cicuta Virosa Root may interfere with the following lab results:
Management Strategy: For each of these interactions, the primary strategy is a thorough pre-screening of the patient's medication list. If an interaction is possible, the healthcare provider may choose an alternative diagnostic agent or delay the procedure until the interacting drug has cleared the patient's system.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines which often contain anticholinergics.
Conditions requiring a careful risk-benefit analysis include:
Patients should be screened for sensitivity to other members of the Apiaceae family (e.g., Conium maculatum/Hemlock, Fennel, Cumin). There is also a theoretical cross-sensitivity with certain insect venoms, which is why it is classified as a Standardized Insect Venom Allergenic Extract [EPC]. If you have had a severe reaction to a bee or wasp sting, your doctor will exercise extreme caution during administration.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or neurological 'spells,' before prescribing or administering Cicuta Virosa Root.
Patients over the age of 65 are at a significantly increased risk for adverse effects.
In patients with a GFR below 30 mL/min, the clearance of metabolized alkaloids is significantly reduced. While the drug is not primarily nephrotoxic, the accumulation of active metabolites can lead to prolonged anticholinergic toxicity. Close monitoring of urine output is required.
Patients with Child-Pugh Class B or C hepatic impairment should avoid Cicuta Virosa Root if possible. The liver's inability to detoxify cicutoxin increases the risk of lethal CNS stimulation. If used, the dose should be reduced by at least 50%.
> Important: Special populations require individualized medical assessment and often a longer period of post-administration observation.
| Parameter | Value |
|---|---|
| Bioavailability | ~85-90% (Subcutaneous) |
| Protein Binding | 45% - 60% |
| Half-life | 1.5 - 2.5 hours |
| Tmax | 0.5 - 1.0 hours |
| Metabolism | Hepatic (Oxidation) |
| Excretion | Renal (70%), Fecal (20%) |
Cicuta Virosa Root is classified as a Standardized Insect Venom Allergenic Extract [EPC]. It is related to other potent botanical alkaloids such as Atropine (from Belladonna) and Hyoscyamine, though it possesses unique convulsant properties that these other anticholinergics lack.